Pharmaceutical Policy In Countries With Developing Healthcare Systems
Pharmaceutical Policy In Countries With Developing Healthcare Systems Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Pharmaceutical Policy In Countries With Developing Healthcare Systems book. This book definitely worth reading, it is an incredibly well-written.
Pharmaceutical Policy in Countries with Developing Healthcare Systems by Zaheer-Ud-Din Babar Pdf
A comprehensive and granular insight into the challenges of promoting rational medicine, this book serves as an essential resource for health policy makers and researchers interested in national medicines policies. Country-specific chapters have a common format, beginning with an overview of the health system and regulatory and policy environments, before discussing the difficulties in maintaining a medicines supply system, challenges in ensuring access to affordable medicines and issues impacting on rational medicine use. Numerous case studies are also used to highlight key issues and each chapter concludes with country-specific solutions to the issues raised. Written by highly regarded academics, the book includes countries in Africa, Asia, Europe, the Middle East and South America.
A Practical Approach to Pharmaceutical Policy by Andreas Seiter Pdf
This book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for developing policies that improve access to safe, effective medicines in health systems of low- and middle-income economies.
Equitable Access to High-Cost Pharmaceuticals by Zaheer-Ud-Din Babar Pdf
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest
Pharmaceuticals and Health Policy by Richard Blum,Andrew Herxheimer,Catherine Stenzl,Jasper Woodcock Pdf
Originally published in 1981, this comprehensive volume is intended for medical economists, clinical pharmacologists, physicians, pharmacists and consumers, as well as planner and administrators who must determine relevant policy and legislation in the area of the provision of medicines. The contributors believe that the system of drugs provision can benefit from being studied, by policy revisions and evaluation of the outcomes of policy operations.
WHO guideline on country pharmaceutical pricing policies by Anonim Pdf
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
National Medicines Policy: A Malaysian Perspective (Penerbit USM) by Salmah Bahri,Mohamed Izham Mohamed Ibrahim Pdf
As part of the health policy of a country, national medicine policy should be an essential section which aimed at rational use of pharmaceuticals. World Health Organization supports country to develop, implement and monitor the effectiveness of national medicines policy’s guidelines, strategies and plans. A good and effective national medicine policy will ensure the availability, affordability, accessibility and rational usability of essential medicine, and traditional, complementary and alternative medicine. National medicine policy will make sure that medicines in the country are not only safe, effective and of good quality, but they must also be cost effective. When this book was written, Malaysia still has not had any comprehensive document on the national medicine policy. A study was conducted to evaluate the status of the pharmaceutical sector in relation to the national medicine policy components. This book provides information about the status of medicine policy in the country and to what extent the medicine policy makers recognize and are aware of the existence of medicine policy in the country. How can we expect for effective and reliable policies, if policy makers do not know or are not sure about the national medicine policy and the various medicine policies available in the country! The book is designed for academicians, practitioners, students, as well as policy makers in the health care institutions. The authors hope that these group of readers will appreciate the significant contribution of effective and reliable medicine policy for a country, especially for the developing nations.
Frederick M. Abbott,Maurice Nelson Graham Dukes,Graham Dukes
Author : Frederick M. Abbott,Maurice Nelson Graham Dukes,Graham Dukes Publisher : Edward Elgar Publishing Page : 319 pages File Size : 53,8 Mb Release : 2009-01-01 Category : Law ISBN : 9781849801843
Global Pharmaceutical Policy by Frederick M. Abbott,Maurice Nelson Graham Dukes,Graham Dukes Pdf
There is a strong argument that people throughout the world have a right to receive the medicines they need in an appropriate, affordable, and timely way. Global Pharmaceutical Policy describes the laws, policies, and customs relating to the development and provision of medicines, identifies their strengths and weakness, and then proposes global solutions for getting things better. Here is a masterpiece written in a clear and elegant style. Together, Dukes and Abbott have experience and insight that are unrivalled. Joe Collier, Emeritus Professor of Medicines Policy, St George s, University of London, UK Pharmaceuticals play a central role in health care throughout the world. The pharmaceutical industry is beset with difficulties as increasing research and development expenditure yields fewer new treatments. Public and private budgets strain under the weight of high prices and limited access. The world s poor see little effort to address diseases prevalent in less affluent societies, while the world s wealthy are overusing prescription drugs, risking their health and wasting resources. As the global economic crisis exacerbates pressure on health care budgets, a new presidential administration in Washington, DC has committed to broad health care reform. These circumstances form the backdrop for this extraordinarily timely examination of the global system for the development, production, distribution and use of medicines. The authors are acknowledged experts in the fields of pharmaceutical law and policy, with many years experience advising governments, multilateral organizations and policy-makers on issues involving innovation, access and use of medicines. Supported by a team of independent scientists, doctors and lawyers, they take an insightful look at the issues surrounding global regulation of the pharmaceutical sector, and offer pragmatic suggestions for reform. This book will be of interest to government policy-makers, members of industry, healthcare professionals, teachers, students and lawyers in the fields of public health, intellectual property and international trade.
Pharmaceutical Systems by John Lilja,Sam Salek,Aldo Alvarez,David Hamilton Pdf
Offers a social view of the activities leading to the timely patient access to medicines including: drug research, drug production, drug distribution, drug prescribing, drug information and drug control Provides theoretical models to enable pharmacists to understand the organization of drug systems in their particular global territory Written specifically with the needs of pharmacy students taking Master's degrees in mind
Author : World Health Organization Publisher : World Health Organization Page : 104 pages File Size : 51,5 Mb Release : 2001 Category : Law ISBN : 924154547X
How to Develop and Implement a National Drug Policy by World Health Organization Pdf
A drug policy is a crucial ingredient in every country's national health strategy as it provides a strategic framework to identify goals and commitments. This publication discusses the key components of such a policy. Issues covered include: the selection of essential drugs, affordability; finance and supply; regulation and quality assurance; rational use; research; human resources; monitoring and evaluation.
Managing Pharmaceuticals in International Health by Stuart Anderson,Reinhard Huss,Rob Summers,Karin Wiedenmayer Pdf
-Gives a new perspective on the politics of drug supply -Will interest those involved with the management of medicines at any level -Indispensable for students of public health
Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity And Quality by Mossialos, Elias,Mrazek, Monique,Walley, Tom Pdf
"This thoughtful and comprehensive book represents the best work I have seen on the current situation concerning medication policies in the EU. It is not just that this is a very up-to-date compendium of facts and data across a wide variety of domains that impact on pharmaceutical regulation. The book is also strong on analysis of those facts as well." Jerry Avorn, Harvard Medical School. "This book offers a comprehensive examination of approaches to manage pharmaceutical expenditures in Europe. It is a must-read for those who seek to understand and navigate the changing regulatory environment for medicines in the European Union." Bernie O'Brien, McMaster University, Canada. The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure across Europe and what impact these strategies have had on efficiency, quality, equity and cost of pharmaceutical care.Regulating Pharmaceuticals in Europe is an important book for students of health policy, regulation and management, and for health managers and policy makers. The editors: Elias Mossialos is Brian Abel-Smith Professor of Health Policy at the London School of Economics and Political Science and a Research Director of the European Observatory on Health Systems and Policies. Monique Mrazek is a Health Economist (Europe and Central Asia region) for the World Bank and formerly a Research Officer in Health Economics for the European Observatory on Health Systems and Policies. Tom Walley is Professor of Clinical Pharmacology at the University of Liverpool and Director of the UK National Health Technology Assessment Programme. Contributors:Julia Abelson, Christa Altenstetter, Vittorio Bertele’, Christine Bond, Marcel L. Bouvy, Colin Bradley, Steve Chapman, Anna Dixon, Michael Drummond, Pierre Durieux, Edzard Ernst, Armin Fidler, Eric Fortess, Richard Frank, Silvio Garattini, Leigh Hancher, Ebba Holme Hansen, Steve Hudson, Kees de Jonchere, Panos Kanavos, Sjoerd Kooiker, Jean-Marc Leder, Graham Lewis, Donald W. Light, Alistair McGuire, Elias Mossialos, Monique Mrazek, Maria Pia Orru', Govin Permanand, Guenka Petrova, Munir Pirmohamed, Dennis Ross-Degnan, Frans Rutten, Steven Soummerai, David Taylor, Sarah Thomson, Tom Walley.
Author : Marc J. Roberts Publisher : World Bank Publications Page : 357 pages File Size : 54,5 Mb Release : 2011-09-21 Category : Medical ISBN : 9780821387603
This book applies an established analytical framework for health sector reform (Getting Health Reform Right, Oxford, 2004) to the performance problems of the pharmaceutical sector. The book is divided into three sections. The first section presents the basic ideas for analysis. It begins by insisting that reform start with a clear understanding of the performance deficiencies of the current system. Like all priority setting in the public sector, this 'definition of the problem' involves both ethical choices and political processes. Early chapters explain the foundations of these ideas and apply them to the pharmaceutical sector. The relationship of ultimate outcomes (like health status or risk protection) to classic health systems concepts like efficiency, access and quality is also explored. The last chapter in the first part is devoted to 'diagnosis'—explaining how to move from the definition of a problem to an understanding of how the functioning of the system produces the undesirable outcomes in question. The second part of the book devotes one chapter to each of five 'control knobs': finance, payment, organization, regulation and persuasion. These are sets of potential interventions that governments can use to improve pharmaceutical sector performance. Each chapter presents basic concepts and discusses examples of reform options. Throughout we provide 'conditional guidance'—avoiding the approach of a 'one size fits all' model of 'best practices' in these five arenas for reform. Instead we stress the need for local knowledge of political systems, administrative capacities, community values and market conditions in order to design pharmaceutical sector policies appropriate to a country’s particular circumstances. The last part of the book is a set of teaching cases. Each is preceded by questions and is followed by a brief note on the lessons to be learned. The goal is to help readers develop the skills they need to deal effectively with pharmaceutical sector reform problems in their own countries.
Author : Nick Freemantle,Suzanne Hill Publisher : John Wiley & Sons Page : 280 pages File Size : 46,9 Mb Release : 2008-04-15 Category : Medical ISBN : 9781405140973
Evaluating Pharmaceuticals for Health Policy and Reimbursement by Nick Freemantle,Suzanne Hill Pdf
“The challenge in all settings is to make the difficultdecisions in a way that is defensible, justifiable, ethical, andequitable” So write Nick Freemantle and Suzanne Hill in their introductionto this important discussion on decision making in thereimbursement of pharmaceuticals. Based around a programmesupported by the World Health Organization, chapters by leadingacademics involved in the research tackle such major issues asinternational pharmaceutical policy, tensions in licensingpolicies, priority setting, and relationships between thestakeholders. Chapters include Development of marketing authorisation procedures forpharmaceuticals Interpreting clinical evidence International pharmaceutical policy: health creation or wealthcreation? Development of fourth hurdle policies around the world Economic modelling in drug reimbursement Priority setting in health care: matching decision criteriawith policy objectives Tensions in licensing and reimbursement decisions: case ofriluzole for amytrophic lateral sclerosis Relationship between stakeholders: managing the war ofwords Medicine and the media: good information or misleadinghype? How to promote quality use of cost-effective medicines Using economic evaluation to inform health policy andreimbursement: making it happen and making it sustainable Pricing of pharmaceuticals Evaluating pharmaceuticals for health policy in low and middleincome country settings. Besides the controversial issues there is a wealth of practicalinformation including economic modelling and the experiences fromthe WHO programme, providing readers with workable examples. Thisis essential reading for clinical researchers in pharmaceuticalsand policy makers everywhere.